Quantitative and qualitative methods of evaluating response to biologics in severe asthma patients: Results from a real-world study

Abstract

[EN] Asthma is a complex major noncommunicable disease affecting around 333 million people worldwide, both children and adults.New biological therapies for treating severe asthma have remarkably improved disease management. Notwith-standing, one remaining crucial problem is evaluating the response to these treatments. Therefore, adequate measurement of the response to biologics in a holistic manner that integrates clinical variables of interest and quality of life is needed, particularly in identifying super-responder patients (SR). Menzies-Gow et al went more profound in the concept and proposed a consensus to evaluate remission.